PDS Biotechnology Corporation announced on October 18, 2026, that it has appointed three new directors to its Board of Directors, filling vacancies created by the resignations of five existing members. The resignations of Kamil Ali-Jackson, Esq., Stephen Glover, Gregory Freitag, J.D., CPA, and Otis Brawley, M.D., were effective immediately, with the company stating that the departures were not the result of disagreements regarding operations or policies.
The newly appointed directors are Deborah A. Ramsdell, John A. Dawson CBE, and Bruce Wendel. The Board has fixed its authorized number of directors at seven. Ms. Ramsdell was appointed as a Class A director to serve until the 2027 Annual Meeting of Stockholders. Mr. Dawson was appointed as a Class B director to serve until the 2029 Annual Meeting of Stockholders. Mr. Wendel was appointed as a Class C director to serve until the 2028 Annual Meeting of Stockholders.
The company noted that each new director is independent under Nasdaq listing standards. Deborah A. Ramsdell brings more than 35 years of experience in rare disease drug development and has served as the Chief Executive Officer of Pluvia Biotech since August 2026. John A. Dawson CBE has served as Executive Chair of Virocell Therapeutics since March 2023 and previously served as Chief Executive Officer of Oxford Biomedica plc from 2008 to 2022. Bruce Wendel has held leadership roles at Bristol-Myers Squibb, Abraxis BioScience, and IVAX Corporation, and previously served on the boards of GT BioPharma and Verastem.
In connection with their appointments, each new director received a nonqualified stock option to purchase 22,700 shares of the company's common stock. The options vest in three annual installments over three years. The Board also reconstituted its committee memberships, with Mr. James Banaag serving as Chair of the Audit Committee, Dr. Patrick Soon-Shiong as Chair of the Compensation Committee, and Mr. Bruce Wendel as Chair of the Nominating and Corporate Governance Committee.
